6241 - 6250 of 9145 Results
Title
Year
-
OPENTitle: Parkinson’s Patients’ Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique StudyJournal Name: MDM Policy & PracticePublisher: SAGE PublicationsVol: 6Issue #: 1Start Page: 2381468320978407End Page: 2381468320978407Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/2381468320978407Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/2381468320978407Citation Count: 23
-
OPENTitle: Recruitment for Remote Decentralized Studies in Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 1Start Page: 371End Page: 380Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-212935Best OA location URL: https://escholarship.org/uc/item/0k98f47rCitation Count: 22
-
OPENTitle: Using Qualitative Methods to Understand Physical Activity and Weight Management Among Bangladeshis in New York City, 2013Journal Name: Preventing Chronic DiseasePublisher: Centers for Disease Control and Prevention - Preventing Chronic DiseaseVol: 13Issue #:Start Page: E87End Page: E87Publication Date:Open Access(OA) Status: OPENLicense: public-domainDOI - Digital Object Identifier: 10.5888/pcd13.160077Best OA location URL: https://www.cdc.gov/pcd/issues/2016/pdf/16_0077.pdfCitation Count: 23
-
OPENTitle: The Experience of OFF Periods in Parkinson’s Disease: Descriptions, Triggers, and Alleviating FactorsJournal Name: Journal of Patient-Centered Research and ReviewsPublisher: Aurora Health Care, Inc.Vol: 8Issue #: 3Start Page: 232End Page: 238Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.17294/2330-0698.1836Best OA location URL: https://institutionalrepository.aah.org/cgi/viewcontent.cgi?article=1836&context=jpcrrCitation Count: 18
- Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial2023RESTRICTEDTitle: Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trialJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 114Issue #:Start Page: 105511End Page: 105511Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105511Citation Count: 13
-
OPENTitle: Understanding the Lexicon of Fatigue in Parkinson’s DiseaseJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 10Issue #: 3Start Page: 1185End Page: 1193Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3233/jpd-202029Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd202029?id=journal-of-parkinsons-disease%2Fjpd202029Citation Count: 15
-
OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 41
- DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.2017RESTRICTEDTitle: DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.Journal Name: NeuropharmacologyPublisher: Elsevier BVVol: 131Issue #:Start Page: 116End Page: 127Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2017.11.046Citation Count: 20
-
OPENTitle: Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson’s diseaseJournal Name: Stem Cell ResearchPublisher: Elsevier BVVol: 60Issue #:Start Page: 102733End Page: 102733Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.scr.2022.102733Best OA location URL: https://doi.org/10.1016/j.scr.2022.102733Citation Count: 8
-
OPENTitle: Lack of association between G6PD variants and Parkinson diseaseJournal Name: Human Genetics and Genomics AdvancesPublisher: Elsevier BVVol: 7Issue #: 1Start Page: 100555End Page: 100555Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.xhgg.2025.100555Best OA location URL: https://doi.org/10.1016/j.xhgg.2025.100555Citation Count: 0